

CONTACT | Media:

+31.20.550.4488 (Amsterdam), +32.2.509.1392 (Brussels)
 +351.217.900.029 (Lisbon), +44.20.7379.2789 (London)
 +1.212.656.2411 (New York), +33.1.49.27.11.33 (Paris)

CONTACT | Investor Relations:

+1.212.656.5700 (New York)
 +33.1.49.27.58.60 (Paris)

NYSE Euronext verwelkomt Cryo-Save op haar Europese markt

Europa's meest toonaangevende stamcelbank krijgt vandaag notering aan NYSE Euronext

Amsterdam, 22 oktober 2009 – Sinds vandaag is Europa's meest toonaangevende stamcelbank Cryo-Save Group N.V. (NYSE Euronext: CRYO) genoteerd aan de Amsterdamse beurs van NYSE Euronext. Het hoofdkantoor van Cryo-Save is gevestigd in Nederland.

Cryo-Save heeft opslagfaciliteiten in 5 landen en is actief in 38 landen in Europa, Azië en Afrika. Met meer dan 115.000 opgeslagen stalen is Cryo-Save Europa's grootste volwassen stamcelbank. Het bedrijf streeft ernaar in de toekomst een belangrijke bijdrage te leveren in de strijd tegen levensbedreigende ziektes voor kinderen en volwassenen en hanteert daarom de hoogste kwaliteitsnormen in de opslag van stamcellen. Door deelname aan projecten van de Europese Commissie en samenwerking met universiteiten en ziekenhuizen wil het bedrijf haar cryopreservatietechnieken verder verbeteren.

De aandelen van Cryo-Save worden op NYSE Euronext verhandeld onder het ticker symbool 'CRYO' en worden genoteerd in Euro's. De eerste koers van het aandeel na de opening was € 6,30. Gebaseerd op het totaal aantal uitstaande aandelen (9.639.191) bedroeg de marktkapitalisatie van de onderneming bij opening € 60.726.903.

Marc Waeterschoot, CEO van Cryo-Save zei: "Als Nederlandse onderneming, met de meeste activiteit op het vaste continent, vergroot een notering aan NYSE Euronext onze zichtbaarheid en liquiditeit. Daarmee is de notering een meerwaarde voor ons bedrijf en voor de aandeelhouders die in ons geïnvesteerd hebben sinds onze notering aan AIM in Londen in 2007".

"Wij heten Cryo-Save van harte welkom op de Europese markt van NYSE Euronext, de grootste en meest liquide markt in Europa. Als meest toonaangevende stamcelbank in Europa krijgt Cryo-Save op deze manier ongeëvenaarde toegang tot beleggers in de eurozone," zei Joost van der Does de Willebois, voorzitter van Euronext Amsterdam.

Media contacten:

NYSE Euronext (Amsterdam):

Alice Jentink +31 (0)20 5504488

Cryo-Save Group NV:

Arnoud van Tulder (CFO) +31 (0)575 548998

About Cryo-Save N.V.

With more than 115,000 samples saved, Cryo-Save is the leading stem cell bank in Europe and one of the fastest growing in the world. Driven by its international business strategy, Cryo-Save is now represented in 38 countries on three continents and has state-of-the-art processing facilities in Belgium, Germany, Dubai, India and France (under construction).

Cryo-Save sets the highest quality standards in stem cell storage, as it aims to make an important contribution to conquer possible life-threatening diseases in the future. As a service to the public, Cryo-Save offers a Cost-free Family Donation Programme, free of charge, to families wishing to store their newborn's umbilical cord blood stem cells for a family member diagnosed with a life-threatening disease treatable by stem cells. The company is committed to further improve stem cell cryopreservation techniques, by participating in European Commission funded projects, in Universities and Hospitals.

About NYSE Euronext

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With more than 8,000 listed issues, NYSE Euronext's equities markets -- the New York Stock Exchange, NYSE Euronext, NYSE Amex and NYSE Alternext, as well as NYSE Arca -- represent nearly 40 percent of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, the leading European derivatives business and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the S&P 100 index and Fortune 500. For more information, please visit: <http://www.nyx.com>

Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning NYSE Euronext's plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forward-looking statements are based on NYSE Euronext's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause NYSE Euronext's results to differ materially from current expectations include, but are not limited to: NYSE Euronext's ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk and U.S. and global competition, and other factors detailed in NYSE Euronext's reference document for 2008 ("document de référence") filed with the French Autorité des Marchés Financiers (Registered on April 28, 2009 under No. R. 09-031), 2008 Annual Report on Form 10-K and other periodic reports filed with the U.S. Securities and Exchange Commission or the French Autorité des Marchés Financiers. In addition, these statements are based on a number of assumptions that are subject to change. Accordingly, actual results may be materially higher or lower than those projected. The inclusion of such projections herein should not be regarded as a representation by NYSE Euronext that the projections will prove to be correct. This press release speaks only as of this date. NYSE Euronext disclaims any duty to update the information herein.